| Size | Price | |
|---|---|---|
| 100mg | ||
| 500mg |
| Targets |
Dofequidar fumarate competitively inhibits ABCB1/P-glycoprotein and ABCC1/MRP-1. It binds to the drug-binding site of the transmembrane P-gp efflux pump. By blocking efflux, it increases the accumulation of cytotoxic drugs such as vincristine, docetaxel, and doxorubicin in resistant cancer cells. It also inhibits sphingomyelin synthase, contributing to its MDR-reversing activity.
|
|---|---|
| ln Vitro |
In vitro, dofequidar fumarate completely reverses resistance against vincristine in multidrug-resistant variants of mouse leukemia P388 cells and human leukemia K562 cells at concentrations of 1-10 µM. At 3 µM, it effectively overcomes docetaxel resistance in MDR cancer cells, achieving blood concentrations comparable to clinically achievable levels. It significantly enhances the cytotoxicity of chemotherapeutic agents in ABCB1/P-gp-expressing and ABCC1/MRP1-expressing cancer cell lines.
|
| ln Vivo |
In vivo, dofequidar fumarate is orally active and has demonstrated efficacy in overcoming multidrug resistance in preclinical tumor models. When co-administered with conventional chemotherapeutic agents, it increases drug accumulation in tumor tissues and enhances antitumor activity. It reverses MDR in animal models bearing P-gp-expressing and MRP1-expressing tumors. The compound has been evaluated in clinical trials for multidrug-resistant tumors, showing potential to improve chemotherapy outcomes.
|
| Enzyme Assay |
P-glycoprotein ATPase activity is measured using membrane vesicles expressing recombinant P-gp. Dofequidar fumarate is incubated with vesicles, ATP, and a fluorescent substrate. ATP hydrolysis is quantified by measuring inorganic phosphate release. For competitive binding assays, a radiolabeled P-gp substrate such as [3H]-vinblastine is incubated with P-gp-enriched membranes and increasing concentrations of dofequidar. Bound radioactivity is measured by liquid scintillation counting, and IC50 values are determined.
|
| Cell Assay |
Multidrug-resistant cancer cell lines (P388/VCR, K562/ADM) are cultured in RPMI-1640 with fetal bovine serum. Cells are seeded and treated with fixed concentrations of chemotherapeutic agents (vincristine, docetaxel, doxorubicin) in the presence of serial dilutions of dofequidar fumarate. After 48-72 hours, cell viability is measured by MTT assay. The reversal fold is calculated as the ratio of IC50 values with and without dofequidar. Intracellular drug accumulation is measured by flow cytometry or radiolabeled drug uptake assays.
|
| Animal Protocol |
Mice bearing multidrug-resistant tumors are used. Dofequidar fumarate is administered orally alone or in combination with chemotherapeutic agents such as vincristine or docetaxel. Tumor volume is measured regularly. Body weight and survival are monitored. For pharmacokinetic studies, blood samples are collected at various time points after oral administration, and plasma drug concentrations are determined by HPLC or LC-MS/MS. The compound demonstrates oral bioavailability and achieves effective blood concentrations for MDR reversal.
|
| References |
|
| Additional Infomation |
Dofequidar fumarate is a synthetic quinoline derivative with multidrug resistance (MDR) modulating properties. Like many other MDR reversals, Dofequidar fumarate competitively binds to the drug-binding site of the transmembrane P-glycoprotein efflux pump (P-gp). Once bound to the P-gp efflux pump, Dofequidar is transported out of transformed cells via a mechanism similar to that of cytotoxic drugs, thereby blocking the efflux of these compounds from the cell. This inhibition of the P-gp efflux pump leads to cytotoxic drug retention, increasing intracellular drug concentrations and thus enhancing cytotoxicity. Dofequidar has been shown to reverse the MDR phenotype in cells exposed to various chemotherapeutic agents, such as vinca alkaloids and anthracyclines.
|
| Molecular Formula |
C72H74N6O18
|
|---|---|
| Molecular Weight |
1311.4
|
| Exact Mass |
1310.51
|
| CAS # |
158681-49-3
|
| PubChem CID |
11979781
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
720.8ºC at 760mmHg
|
| Flash Point |
389.7ºC
|
| Vapour Pressure |
8.36E-22mmHg at 25°C
|
| LogP |
6.788
|
| tPSA |
355.6
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
96
|
| Complexity |
771
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(/C=C/C(=O)O)=O.OC(/C=C/C(=O)O)=O.OC(/C=C/C(=O)O)=O.OC(CN1CCN(C(C(C2C=CC=CC=2)C2C=CC=CC=2)=O)CC1)COC1=CC=CC2N=CC=CC1=2.OC(CN1CCN(C(C(C2C=CC=CC=2)C2C=CC=CC=2)=O)CC1)COC1=CC=CC2N=CC=CC1=2
|
| InChi Key |
ZGMJYTYLTJFNCS-VQYXCCSOSA-N
|
| InChi Code |
InChI=1S/2C30H31N3O3.3C4H4O4/c2*34-25(22-36-28-15-7-14-27-26(28)13-8-16-31-27)21-32-17-19-33(20-18-32)30(35)29(23-9-3-1-4-10-23)24-11-5-2-6-12-24;3*5-3(6)1-2-4(7)8/h2*1-16,25,29,34H,17-22H2;3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+
|
| Chemical Name |
(E)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone
|
| Synonyms |
MS 209 fumarate; MS-209 fumarate; Dofequidar fumarate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7625 mL | 3.8127 mL | 7.6254 mL | |
| 5 mM | 0.1525 mL | 0.7625 mL | 1.5251 mL | |
| 10 mM | 0.0763 mL | 0.3813 mL | 0.7625 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.